Company news

Cocrystal Pharma, Inc. news in 2022

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

December 18, 2022

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

November 30, 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

November 16, 2022

Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

November 13, 2022

Cocrystal Pharma to Participate in Two Investor Conferences in November

November 1, 2022

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

October 31, 2022

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344

October 25, 2022

Cocrystal Pharma to Present at the LD Micro Main Event XV

October 18, 2022

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

October 12, 2022

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

October 10, 2022

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

October 4, 2022

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

October 2, 2022

Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

August 14, 2022

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

August 7, 2022

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

August 2, 2022

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

July 13, 2022

Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

May 31, 2022

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

May 10, 2022

Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

April 20, 2022

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

April 18, 2022

Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference

April 13, 2022

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

April 11, 2022

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

March 22, 2022

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

March 21, 2022

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

March 9, 2022

Cocrystal Pharma to Participate in Upcoming Investment Conferences

March 2, 2022

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

January 26, 2022

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

January 5, 2022

Cocrystal Pharma to Present at the H.C. Wainwright BioConnect Virtual Conference

January 3, 2022

Decks in 2022